1d
GlobalData on MSNImmunovant will not seek approval for MG therapy, despite hitting endpointsThe company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...
Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...
Amifampridine tablets are indicated for the treatment of Lambert-Eaton myasthenic syndrome in adults and pediatric patients 6 ...
Immunovant (IMVT) reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study ...
Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in ...
RSSFACTS: The RSS's centenary celebrations, set for 2025-2026, focus on expanding its core principles, including societal ...
The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.
23h
India Today on MSNBengaluru man goes on lengthy rant about why living in the city has become irritableIn the Reddit post titled "Why living in Bengaluru has become irritable recently," the user ‘Normal_Excuse_6303’ cited ...
17h
Verywell Health on MSNDash Diet vs. Mediterranean Diet: Which Is Better for Your Health?The DASH diet has long been hailed as the ideal diet for people with hypertension. However, the Mediterranean diet offers ...
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a collaboration LOI ...
BluSmart Mobility restructures operations, sells electric vehicles to Refex, and focuses on fleet growth while aiming for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results